FDA Approves First Biosimilar, Still No Guidance on Names

The Food and Drug Administration has approved the first biosimilar therapy in the U.S.

There is a rough – but very imperfect – parallel between biosimilars and generic drugs, which now make up the vast majority of prescriptions filled in the U.S. The innovative biotech industry long argued that it was harder to make a generic biologic therapy than a generic drug, because the former is made from living sources, not just molecules.

Read the entire column at NCPA's Health Policy Blog.